Researchers sought to determine whether adding nivolumab to R-CHOP would be safe and effective in the previously untreated DLBCL setting.

Dexamethasone pretreatment reduces GI complications in DLBCL patients with GI involvement without compromising efficacy. The study showed no significant differences in response rates or survival ...

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival. The addition of Revlimid (lenalidomide) to standard ...

Thomas M. Habermann, MD, is a hematologist with the Mayo Clinic in Rochester, Minnesota. A member of the Lymphoma Research Foundation Scientific Advisory Board, Habermann is well known as the lead ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

R CHOP re treatment offers durable responses in patients with late relapse diffuse large b cell lymphoma, with a 2-year time ...

Eligible patients were adults with newly diagnosed untreated stages II to IV CD20 + DLBCL. Patients received lenalidomide 25 mg orally per day on days 1 through 10 with standard-dose R-CHOP every 21 ...

R-CHOP plus ibrutinib followed by ibrutinib maintenance induced an ORR of 90% after 4 cycles and 85% at the end of induction. Adding ibrutinib to standard-of-care (SOC) R-CHOP resulted in a 77.7% ...

The combination of Epkinly and R-mini-CHOP showed a 93% ORR and 86% CR rate in elderly DLBCL patients. At two years, 79% of patients remained in complete response, with a 76% progression-free survival ...

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial The combination of ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...